Navigation Links
Cardica to Announce Fiscal 2008 Second Quarter Financial Results on Thursday, January 24, 2008
Date:1/18/2008

rd-protected event management site.

About Cardica, Inc.

Cardica is a leading provider of automated anastomosis systems for coronary artery bypass graft (CABG) surgery. By replacing hand-sewn sutures with easy-to-use automated systems, Cardica's products provide cardiovascular surgeons with rapid, reliable and consistently reproducible anastomoses, or connections of blood vessels, often considered the most critical aspect of the CABG procedure. Cardica's C-Port(R) Distal Anastomosis Systems are marketed in Europe and the United States. The PAS-Port(R) Proximal Anastomosis System is marketed in Europe and Japan and is being evaluated in a pivotal trial in the United States and Europe. Cardica also is developing additional devices with Cook Incorporated to facilitate vascular closure and other surgical procedures.


'/>"/>
SOURCE Cardica, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. Cardica Announces Proposed Public Offering of Common Stock
2. Cardica Announces Pricing of $34.7 Million Public Offering of Common Stock
3. Cardica Announces Live Webcast Demonstrating Breakthrough Device to Facilitate Beating Heart and Robotic Coronary Revascularization Surgery
4. Cardica Announces Exercise of Over-Allotment Option
5. HHS Announces $75 Million in Supplemental Funding to States for Pandemic Flu Preparedness
6. CRC Health Group Announces Acquisition of Bayside Marin Recovery Center, San Rafael
7. UHW Announces: Antelope Valley Hospital Caregivers and Board Vote to Ratify First Union Contract With SEIU UHW-West
8. HEI, Inc. Announces Sale of RFID Division Assets
9. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
10. Mettler-Toledo International Inc. Announces Webcast of Presentation at Thomas Weisel Partners 2007 Healthcare Conference
11. Z Trim Announces Revocation of Gregory Halpern Severence Agreement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2008)... July 23 /PRNewswire-FirstCall/ - Cardiome Pharma ... it has entered into an,agreement with CR Intrinsi...CR Intrinsic Investors, LLC, an affiliate of S.A.C...rtible preferred shares for gross proceeds of,US$2...for general corporate,purposes, costs associated w...
(Date:7/23/2008)...DNA to create faster, smaller, and more powerful c...scrambling to develop successful ways to use genet...professor at Rensselaer Polytechnic Institute sugg...tations, all we have to do is literally look aroun...rk Changizi has begun to develop a technique to tu...
(Date:7/23/2008)...-USNewswire/ -- The Children,s,Hospital of Philade...ion,gift that will enable the opening of a new ped...is gift, made possible by Athena and Nicholas,Kara... in the history of,Children,s Hospital and will gi...communities convenient access to world-class pedia...
(Date:7/23/2008)... Times may be tough, but,Hollywood,s young stars l...a dazzling new smile to boost confidence. Cosmetic...ty clients beam in on success, citing his,experien...confidence they,need for stardom. In agreement is ...ge smile designed by Dr. Kosdon., MTV,s Rock The ...
Breaking Medicine News(10 mins):Health News:Cardiome Announces Preferred Share Financing 2Health News:Cardiome Announces Preferred Share Financing 3Health News:Study suggests human visual system could make powerful computer 2Health News:Study suggests human visual system could make powerful computer 3Health News:$15 Million Donation From The Karabots Foundation Enables The Children's Hospital of Philadelphia to Open a New Pediatric Care Facility in Norristown, Pennsylvania 2Health News:$15 Million Donation From The Karabots Foundation Enables The Children's Hospital of Philadelphia to Open a New Pediatric Care Facility in Norristown, Pennsylvania 3Health News:Rock The Cradle's Bad Boy Landon Brown Owes His Irresistible New Smile to Dr. Michael Kosdon 2
...t for esophageal reflux disease developed by a Wak...yngologist has been licensed to Bayer HealthCare’s...detects the presence of human pepsin 3b in a patie...man, M.D., then professor of otolaryngology at Wak...
...ld and running nose in children does not merit the...ised. In effect, antibiotics should be administere...tics are known to cause potential side effects. A...pretext, has led to the rise of germs, nicknamed a...
... Safety Authority Medsafe has approved the use of ...eral health professionals are calling for its use ... is said to offer immunity against four strains of...common sexually transmitted infection. Although HP...
...asingly unchecked spread of the HIV/AIDS epidemic ... coming years according to a report on the Macroec...udy was conducted by the National Council of Appli...ed by the the United Nations Development Programme...
Other Medicine News:Health News:Test for Esophageal Reflux Licensed to Bayer by University 2Health News:HIV/AIDS Epidemic to Cause Adverse Effects to Indian Economy 2
(Date:7/22/2008)... July 22 /- Following a,tho...ard of Progen,Pharmaceuticals Limited (ASX: PGL; N...ued the PI-88 phase 3 study in liver cancer. Proge... existing portfolio of compounds and,the company w...and,opportunities through Merger & Acquisition act...
(Date:7/22/2008)...Therapeutics Development Initiative bring MJFF,s,c...deadline January 20,2009, NEW YORK, July 22 /PRN...peed delivery of transformative treatments and a c...undation for Parkinson,s Research has awarded,$2.7... teams. The awards,were granted under MJFF,s Thera...
(Date:7/22/2008)...Study Confirms Tyrima Exhibits Excellent Drug-Like... Results Support Initiation of Phase II Clinical T...RNewswire/ -- CeNeRx BioPharma,Inc., a clinical s...tive,treatments for diseases of the central nervou...d candidate Tyrima(TM) into Phase II trials for th...
(Date:7/22/2008)... Calif., July 22 /- Hyperion,Therapeu...atient enrollment,in its Phase 1/2 clinical trial ...cavenging effects of HPN-100 (formally called GT4P...tients with urea cycle disorders,(UCD). The compan... quarter,of this year., (Logo: http://www.newsco...
Breaking Medicine Technology:Progen Terminates PATHWAY Trial & Confirms Focus on Potential High Value Molecules and M&A 2Progen Terminates PATHWAY Trial & Confirms Focus on Potential High Value Molecules and M&A 3Michael J. Fox Foundation Awards $2.7 Million for Industry Efforts to Speed New Parkinson's Therapeutics 2Michael J. Fox Foundation Awards $2.7 Million for Industry Efforts to Speed New Parkinson's Therapeutics 3CeNeRx BioPharma Finalizes Plans to Initiate Phase II Trials for Its Novel Antidepressant Agent Tyrima(TM) Using Innovative Brain Imaging Study 2CeNeRx BioPharma Finalizes Plans to Initiate Phase II Trials for Its Novel Antidepressant Agent Tyrima(TM) Using Innovative Brain Imaging Study 3CeNeRx BioPharma Finalizes Plans to Initiate Phase II Trials for Its Novel Antidepressant Agent Tyrima(TM) Using Innovative Brain Imaging Study 4Hyperion Therapeutics Completes Enrollment in Phase 1/2 Clinical Trial in Patients With Urea Cycle Disorders 2Hyperion Therapeutics Completes Enrollment in Phase 1/2 Clinical Trial in Patients With Urea Cycle Disorders 3Marital Status Doesnt Affect Lung Cancer Survival 1121 1Marital Status Doesnt Affect Lung Cancer Survival 1121 2Marital Status Doesnt Affect Lung Cancer Survival 1121 3Grubb 26 Ellis Healthcare REIT Acquires Park Place Office Park in Dayton Ohio 8925 1Grubb 26 Ellis Healthcare REIT Acquires Park Place Office Park in Dayton Ohio 8925 2Grubb 26 Ellis Healthcare REIT Acquires Park Place Office Park in Dayton Ohio 8925 3Pennsylvania Invests 2413 4 Million to Kick Off Butler Memorial Hospital Expansion 8923 1Pennsylvania Invests 2413 4 Million to Kick Off Butler Memorial Hospital Expansion 8923 2Eclipsys to Present at 10th Annual Needham Growth Stock Conference 8920 1Eclipsys to Present at 10th Annual Needham Growth Stock Conference 8920 2Eclipsys to Present at 10th Annual Needham Growth Stock Conference 8920 3
...nship Between Ability to Function and Treatment of...DIANAPOLIS, May 21, 2007 /PRNewswire-FirstCall/ --...ty disorder (GAD),treated with Cymbalta(R) (duloxe...everyday activities at home, work and in social,si...s in global,functioning were the result of improve...
...TER, MN, May 21, 2007-- Serotonin is a,neurotransm...yo,Clinic researchers set out to determine the rol... The study involved 48 females --,including indivi...duals with both IBS and dyspepsia, and healthy vol...nd intestines of each,patient and serotonin levels...
Other Medicine Technology:Data Suggest Cymbalta Improved Functioning in Patients with,Generalized Anxiety Disorder 2Data Suggest Cymbalta Improved Functioning in Patients with,Generalized Anxiety Disorder 3Data Suggest Cymbalta Improved Functioning in Patients with,Generalized Anxiety Disorder 4Data Suggest Cymbalta Improved Functioning in Patients with,Generalized Anxiety Disorder 5Data Suggest Cymbalta Improved Functioning in Patients with,Generalized Anxiety Disorder 6
Basic-level interpretive resting ECG
XALATAN is a prescription medicine used to lower eye pressure, also called intraocular pressure, or IOP, in patients with ocular hypertension (abnormally high IOP) or open-angle glaucoma.
The ECG-9010 meets IEC60601-2-51 new international standard for digital electrocardiographs specifying accuracy and digital filter performance. ECG data can be reviewed and managed on a Windows PC wi
The UltraVac V1 allows for unprecedented chamber stability and high vacuum levels with venturi systems. Vacuum and flow are proportionately linked on a venturi pump and cannot be independently adjust
Medicine Products: